Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake

Journal of Clinical Psychopharmacology

Volumn 16, Issue 4, 1996, Pages 273-285

  Harvey, Anne T ^a   Preskorn, Sheldon H ^b  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOMIPRAMINE; CYTOCHROME P450; DESIPRAMINE; DIAZEPAM; IMIPRAMINE; NORCLOMIPRAMINE; PHENAZONE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TOLBUTAMIDE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

BINDING SITE; COMPETITIVE INHIBITION; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME INHIBITION; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL; REVIEW; SMOOTH ENDOPLASMIC RETICULUM;

CYTOCHROME P-450 CYP1A1; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PAROXETINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0030016458     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199608000-00002     Document Type: Review

References (130)

1. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
2. Eichelbaum M, Spannbrucker N, Steincke B, Dengler H. Defective N-oxidation of sparteine in man. A new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
3. Davies D, Kahn G, Murray S, Brodie M, Boobis A. Evidence for an enzyme defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol 1981;11:89-81.
4. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, Gelboin HV, Hardwick JP, Meyer UA. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988;331:442-6.
5. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism - clinical aspects. Pharmacol Ther 1990;46:377-94.
6. Sesardic D, Boobis A, Edwards R, Davies D. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988;26:363-72.
7. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60.
8. Nebert DW, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, Levin W, Phillips IR, Sato R, Waterman MR. The P450 gene superfamily: recommended nomenclature. DNA 1987;6:1-11.
9. Omura T, Sto R, Cooper DY, Rosenthal O, Estabrook W. Function of cytochrome P450 of microsomes. Fed Proc Fed Am Soc Exp Biol 1965;24:1181-9.
10. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
11. Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987;56:945-93.
12. Nebert DW. Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. Mol Endocrinol 1991;5:1203-14.
13. Nebert DW, Nelson DR, Feyereisen R. Evolution of the cytochrome P450 genes. Xenobiotica 1989;19:1149-60.
14. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-52.
15. Wrighton S, Stevens J. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
16. Guengerich FP. Bioactivation and detoxication of toxic and carcinogenic chemicals. Drug Metab Dispos 1993;21:1-6.
17. Kalow W, Tang B. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991;49:44-8.
18. Ged C, Umbenhauer DR, Bellew TM, Bork RW, Srivastava PK, Shinriki N, Lloyd RS, Guengerich FP. Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. Biochemistry 1988;27:6929-40.
19. Lieber CS. Biochemical factors in alcoholic liver disease. Semin Liver Dis 1993;13:136-53.
20. Eichelbaum M, Mineshita S, Ohnhaus E, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22:49-53.
21. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;18:220-39.
22. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, Greb WH. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80[suppl 350]:60-75.
23. Sindrup SH, BřAFsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TCG, Zussman BD. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
24. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden D M, Woosley RL. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.
25. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranotol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
26. Meese C, Fischer C, Eichelbaum M. Stereoselectivity of the 4-hydroxylation of debrisoquine in man, detected by gas chromatography/mass spectrometry. Biomed Environ Mass Spectrom 1988;15:63-6.
27. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 1984;34:73-80.
28. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992;13:434-9.
29. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-31.
30. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988;145:1478.
31. Westermeyer J. Fluoxetine-induced tricyclic toxicity extent and duration. J Clin Psychopharmacol 1991;11:388-92.
32. Wrighton SA, Brian WR, Sari M-A, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, VandenBranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
33. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
34. Watkins PB. Role of cytochromes P450 in drug metabolism and hepatoxicity. Semin Liver Dis 1990;10:235-50.
35. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
36. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992;294:206-14.
37. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28: 373-87.
38. Waxman D, Attisano C, Guengerich P, Lapenson D. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988;263:424-36.
39. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994;33:6450-5.
40. Fuller RW, Rathbun RC, Parli CJ. Inhibition of drug metabolism by fluoxetine. Res Commun Chem Pathol Pharmacol 1976;13: 353-6.
41. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other specific serotonin re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol 1991;32:658P-9P.
42. Gonzalez FJ, Nebert DW. Evolution of the P450 gene superfamily: animal-plant "warfare," molecular drive and human genetic differences in drug oxidation. Trends Genet 1990;6:182-6.
43. Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993;14:292-4.
44. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 1990;45:241-98.
45. Kato R, Yamazoe Y. The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivo. Pharmacogenetics 1994;4:359-62.
46. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988;44:431-5.
47. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17: 102-5.
48. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984;26:753-9.
49. Wrighton S, Stevens J, Becker G, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
50. Goldstein J, Faletto M, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy J, Lasker J, Ghanayem B. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994;33:1743-52.
51. McInnes GT, Brodie MJ. Drug interactions that matter: a critical reappraisal. Drugs 1988;36:83-110.
52. Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988;26:771-80.
53. BřAFsen K, Hansen JG, Neilsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-55.
54. Birgersson C, Morgan E, Jornvall H, von Bahr C. Purification of a desmethylimipramine and debrisoquine hydroxylation cytochrome P-450 from human liver. Biochem Pharmacol 1986;35: 3165-6.
55. Spina E, Birgersson C, von Bahr C, Ericsson O, Mellstrom B, Steiner E, Sjoqvist F. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984;36:677-82.
56. Otton SV, Inaba T, Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 1983;32:795-800.
57. Brøsen K, Gram L. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol 1989;37:155-60.
58. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983;15:388-9.
59. Brøsen K, Klysner R, Gram L, Otton S, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986;30:679-84.
60. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986;40:543-9.
61. Gram LF. Metabolism of tricyclic antidepressants: a review. Dan Med Bull 1974;21:218-31.
62. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
63. Ohmori S, Takeda S, Rikinisa T, Kiuchi M, Kanakubo Y, Kitada M. Studies on cytochrome P450 responsible for oxidative metabolism of imipramine in human liver microsomes. Biol Pharm Bull 1993;16:571-5.
64. Brøsen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991;49:609-17.
65. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991;49:18-23.
66. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
67. Madsen H, Nielsen KK, BřAFsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995;39:433-9.
68. Chiba K, Saitoh A, Koyama E, Tani M, Hayashi M, Ishizaki T. The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994; 37:237-42.
69. Perel JM, Shostak M, Gann E, Kantor SJ, Glassman AH. Pharmacodynamics of imipramine and clinical outcome in depressed patients. In: Gottschalk LA, Merlis S, eds. Pharmacokinetics of psychoactive drugs. New York: Spectrum Publications, 1976:229-41.
70. Balant-Gorgia AE, Schulz P, Dayer P, Balant L, Kubli A, Gertsch C, Garrone G. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr 1982;232:215-22.
71. Mellstrom B, Bertilsson L, Sawe J, Schulz H-U, Sjoqvist F. E- and Z-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
72. Gram L, Brøsen K, Kragh-Sorensen P, Christensen P. Steady-state plaasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent mediation and the sparteine oxidation phenotype. Ther Drug Monit 1989;11:508-14.
73. Nusser E, Nill K, Breyer-Pfaff U. Enantioselective formation and disposition of (E)- and (Z)-10-hydroxynortriptyline. Drug Metab Dispos 1988;16:509-11.
74. Breyer-Pfaff U, Pfandl B, Nill K, Elfriede N, Monney C, Jonzier-Perey M, Baettig D, Baumann P. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isoenzymes. Clin Pharmacol Ther 1992;52:350-8.
75. Sjoqvist F, Bertilsson L. Slow hydroxylation of tricyclic antidepressants - relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP, eds. Ethnic differences in reaction to drugs and xenobiotics. New York: Liss, 1986:169-88.
76. Pfandl B, Morike K, Winne D, Schareck W, Breyer-Pfaff U. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 1992;22:721-30.
77. Dahl M, Nordin C, Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991;13: 189-94.
78. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995;275:592-7.
79. Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986;1: 102-12.
80. Mellstrom B, Sawe J, Bertilsson L, Sjoqvist F. Amitriptyline metabolism: association with debrisoquin hydroxylation in non-smokers. Clin Pharmacol Ther 1986;39:369-71.
81. Mellstrom B, von Bahr C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 1981;9:565-8.
82. Balant-Gorgia AE, Balant LP, Genet Ch, Dayer P, Aeschlimann JM, Garrone G. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986;31:449-55.
83. Hartter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993;110:302-8.
84. Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clin Pharmacokinet 1990;18:434-59.
85. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
86. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
87. von Moltke L, Greenblatt D, Cotreau-Bibbo M, Harmatz J, Shader R. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
88. Smith RB, Gwilt PR, Wright CE III. Single- and multiple-dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharm 1983;2:139-43.
89. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45: 348-55.
90. Greenblatt DJ, Divoll MK, Soong MH, Boxenbaum HG, Harmatz JS, Shader RI. Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. J Clin Pharmacol 1988;28: 853-9.
91. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
92. Ishizaki T, Chiba K, Manabe K, Koyama E, Yasuda S, Horai Y, Tomono Y, Yamato C. Comparison of the effects of E3810 and omeprazole on diazepam pharmacokinetics in extensive and poor metabolizers of S-mephenytoin [abstract]. Clin Pharmacol Ther 1994;55:141.
93. Wilkinson G, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
94. Caraco Y, Tateishi T, Wood AJJ. Ethnic effects on inhibition of drug metabolism [lsab]abstract]. Clin Pharmacol Ther 1994; 55:169.
95. Yasumori T, Nagata K, Yang S, Chen L, Murayama N, Yamazoe Y, Kato R. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993;3:291-301.
96. Andersson T, Miners JO, Birkett DJ, Hassle A. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms [abstract]. Clin Pharmacol Ther 1994;55:138.
97. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991;175:1112-8.
98. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, McManus ME. Relationship between phenytoin and tolbutamide hydroxylations in human Uver microsomes. Br J Clin Pharmacol 1991;31:125-30.
99. Tassaneeyakul W, Veronese M, Birkett D, Doecke C, McManus M, Sansom L, Miners J. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992;34: 494-8.
100. Hansen JM, Kampmann J, Siersback-Nielsen K, Lumholtz I, Arroe M, Abildgaard U, Skovsted L. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 1979;324:106-10.
101. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (part I). Clin Pharmacokinet 1990;18:37-60.
102. Vermeij P, Ferrari M, Buruma O, Veenema H, de Wolff F. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family. Clin Pharmacol Ther 1988;44:588-93.
103. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity. Neurology 1964;14:542-8.
104. Vasko M, Rodney B, Daly D, Pippenger C. Inheritance of phenytoin hypometabolism: a kinetic study of one family. Clin Pharmacol Ther 1994;27:96-103.
105. Riley RJ, Kitteringham NR, Park BK. Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro. Br J Clin Pharmacol 1989;28:482-7.
106. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994;47:1969-79.
107. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986;11:177-98.
108. Pirmohamed M, Kitteringham NR, Guenther TM, Breckenridge AM, Park BK. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem Pharmacol 1992;43:1675-82.
109. Miles MV, Tennison MB. Erythromycin effects on multiple-dose carbamazepine kinetics. Ther Drug Monit 1989;11:47-52.
110. Levy RH, Kerr BM. Clinical pharmacokinetics of carbamazepine. J Clin Psychiatry 1988;49[4 suppl]:58-61.
111. Loft S. Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacol Toxicol 1990; 66[suppl 6]:1-31.
112. Vestal R, Norris A, Tobin J, Cohen B, Shock N, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther 1975;18:425-33.
113. Horsmans Y, Desager J, Pauwels S, Harvengt C. Lack of effect by nifedipine on hepatic mixed function oxidase in man. Fundam Clin Pharmacol 1991;5:193-201.
114. Srivastava P, Yun C, Beaune P, Ged C, Guengerich FP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450. Mol Pharmacol 1991;40:69-79.
115. Relling M, Aoyama T, Gonzalez F, Meyer U. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
116. Veronese M, Doecke C, Mackenzie P, McManus M, Miners J, Rees D, Gasser R, Meyer U, Birkett D. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemistry 1993;289:533-8.
117. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990;47: 403-11.
118. Scott J, Poffenbarger P. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979;28:41-51.
119. Miners J, Wing LMH, Birkett D. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. Aust N Z J Med 1985;15:348-9.
120. Back DJ, Orme ML'E. Genetic factors influencing the metabolism of tolbutamide. Pharmacol Ther 1989;44:147-55.
121. Chen L, Yasumori T, Yamazoe Y, Kato R. Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. Pharmacogenetics 1993;3: 77-85.
122. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
123. Knodell R, Hall S, Wilkinson G, Guengerich F. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987;241:1112-9.
124. Brian W, Srivastava P, Umbenhauer D, Lloyd R, Guengerich F. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 1989;28:4993-9.
125. Lewis R, Trager W, Chan K, Breckenridge A, Orme M, Roland M, Schary W. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J CUn Invest 1974; 53:1607-17.
126. Kunze K, Eddy AC, Gibaldi M, Trager W. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality 1991;3:24-9.
127. Nappi J. Warfarin and phenytoin interaction. Ann Intern Med 1979;90:852.
128. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15: 237-49.
129. Grygiel J, Birkett D. Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther 1981;30:491-6.
130. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine, and theophylline, by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1990;2:73-7.